One of the most common questions we have received from subscribers in the last 6 months relates to Bellicum Pharmaceuticals (NASDAQ: BLCM) and the opportunity for their adjunct T Cell therapy in development for allogeneic hematopoietic stem cell transplantation (HSCT), BPX–501. This product is given after the transplant and uses genetically modified donor T cells incorporating a CaspaCIDe safety switch.
We first wrote an in-depth piece about Bellicum and BPX-501 back in January 2015 with an interview with their CEO and CMO for those interested in more background (Link).
At the recent 2016 BMT Tandem meeting in Hawaii, we had the opportunity to hear the latest data on trends in haplo-identical (Haplo) bone marrow transplants. This posts reviews some of the data presented and considers the implication of this on the market opportunity for Bellicum.
Subscribers can log-in to learn more.
One of the most important challenges in cancer immunotherapy is overcoming immune resistance. For example, even with the high response rates seen in acute lymphoblastic leukemia (ALL) with CAR – T cell therapy, a significant number of patients relapse after an initial response.
Chinatown, Honolulu 2016
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question? Rather than randomly picking ones to try, we need scientific evidence regarding these choices.
This post explores some of the latest data presented at the BMT Tandem meeting on the role of T cell immunoglobulin mucin–3 (TIM–3) and PD–1 upregulation in causing resistance.
If you’re not already a sub and want to read our coverage of ASH, BMT Tandem and the forthcoming AACR 2016 annual meeting, you can purchase individual access below. This week only – inspired by the story of Eddie Aikau in Hawaii – we have a special offer that we’ve never done before (and may never do again) of $75 off a quarterly subscription. The deal ends tomorrow Friday March 4th at 12 noon HST. Check it out!
Subscribers can login to read more about the latest data on how alternative checkpoint inhibitors may have a role to play in cancer treatment. Welcome to the new folks who signed up this week, good to see y’all!
King Kamehameha Statue, Honolulu HI
Honolulu: we’re continuing our coverage of the 2016 BMT Tandem meeting with a thought leader interview about a novel cancer immunotherapy approach that we’re excited about.
The cancer cell therapy landscape is still vastly uncharted territory in many respects.
The first CD19 targeted CAR T cell therapies expected to reach the market in 2017 are unlikely to be best-in-class, which leaves the commercial door open for other approaches that may be better, cheaper or more accessible.
If you are in the CAR T cell therapy space, there are plenty of competitive threats on the horizon, and the novel approach discussed in this post is one of them!
We’d heard a little about it, but hadn’t explored the concept in any detail, so were delighted to talk with a leading expert at the BMT Tandem meeting in Honolulu.
Subscribers can login or you can purchase access to read more about a cell therapy that could offer the benefits of a CAR without the need for genetic modification.
Dr David Porter, U Penn
Honolulu: The BMT Tandem meeting kicked off yesterday with an excellent plenary session on “CAR T Cell Therapy: CD19 and Beyond.” The three presenters were:
- David Porter (University of Pennsylvania) CAR T cells for Leukemia
- Martin Pule (UCL) Building a CAR
- Michael Jensen (Seattle Children’s) CD19-Specific CAR T Cells as a Post-Allo HSCT Relapse Salvage Therapy
Dr Porter (pictured) is Director of the Blood and Marrow Transplant Program at the University of Pennsylvania. I spoke with him after his talk. This post gives a quick overview of some of the key points I took away.
Subscribers can login below or you can purchase access.
Aloha! The BMT Tandem meeting (Twitter #BMTTandem16) is underway in Honolulu, and we’re looking forward to the scientific presentations that start tomorrow, Thursday.
This preview highlights some of the presentations that may be of interest to subscribers at the meeting over the next 5 days when they’re not surfing waves at the North Shore! The meeting ends on Monday Feb 22.
If you can’t make it to Hawaii, then I expect the BMT community will be sharing updates from the meeting via Twitter. Do follow: @DrMiguelPerales, @DrKomanduri, @sgiraltbmtdoc, @DrMvandenBrink, @BldCancerDoc, @MSKBMTTandem & others (this is not intended to be a definitive list, only a starting point).
We won’t be doing a daily blog, but will be generating some commentary and analysis, as the opportunity presents.
Subscribers can login to read more or you can purchase access.
Aloha! If you have plans to be in Honolulu next week for #BMTTandem16, then one of the “must do” sights is the walk to the top of Diamond Head. It towers over Waikiki and is a major landmark for anyone travelling in an easterly direction.
One way to get there is to start early and take the #23 The Bus ($2.50 fare, exact change) from Ala Moana & Waikiki to the state park entrance. The path starts off deceptively easy, kicks in with some uneven surfaces and hits you with a pile of steps near the top. Sensible shoes, water and sunscreen recommended.
The spectacular views at the end are well worth it, especially if you catch the sunrise/early morning light and manage to avoid arriving at the summit at the same time as busloads of Japanese tourists with the same idea. It’s a popular attraction!
One of the reasons for going to the top of hills and mountains is to see the “big picture” of the landscape below. In writing and reporting on the latest innovations in biomedicine, we often focus on the results of one trial or news from one company; yet it’s also important to see how the pieces of the jigsaw fit together.
That’s why pharmaceutical marketers and new produce development specialists often commission custom reports that review the strategic landscape in a therapeutic area.
As part of our coverage of #BMTTandem16, we’re taking a look at some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space.
It’s an area of unmet medical need and market opportunity.
Anyone with an interest in allogeneic “off the shelf” CAR-T cell therapy should already appreciate the significance of GvHD as a potential complication. If you don’t, then you’ve not been reading BSB…
In case you missed it, do listen to Dr Marcel van den Brink talking about GvHD on the Novel Targets Podcast. (Episode 9: Targeting the Microbiome)
This post is not intended to be a substitute for a landscape report, but offers some top line thoughts on some of the strategic drivers to look out for.
Subscribers can login to read more or you can purchase access.